Researchsemaglutidecraniopharyngiomapaediatric obesityhypothalamic obesity

Semaglutide reversed weight gain in 20 children with craniopharyngioma obesity

Across French centres, BMI fell 2.5 kg/m2 over a year of off-label treatment after rising 3.5 kg/m2 in the preceding year.

By Priya Raman · Science Reporter

Sep 27 20:00 ETSource: Diabetes, obesity & metabolism

The wire

01In a multicentre retrospective series of 20 patients under 18 with craniopharyngioma-related obesity, off-label semaglutide titrated to 0.25-2 mg weekly cut BMI by 2.5 kg/m2 and Z-score by 0.5 at 12 months.
02Hypothalamic obesity after craniopharyngioma has few treatment options, and 40% of patients saw BMI fall by 10% or more with only mild gastrointestinal side effects in 30%.
03The series is retrospective and small, drawn from 139 children with craniopharyngioma, with no control group and no long-term data on pituitary function or tumour recurrence beyond one year.

From the source

Semaglutide for Treating Paediatric Craniopharyngioma-Related Obesity: A Multicentre Case Series
Diabetes, obesity & metabolism · 2026 Sep 28 · Dornberger J, Barat P, Aouchiche K et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42806285/